Official statement from Randox on Covid-19 testing

Home - Official statement from Randox on Covid-19 testing

News       About Us        Randox Biochip

 

03 April 2020

 

OFFICIAL STATEMENT FROM RANDOX

On the emergence of the Covid-19 threat Randox utilised their years of regulated diagnostic experience to quickly develop and robustly validate a test for the Covid-19 virus.  Randox had significant confidence in this test and presented them to Public Health England (PHE) for evaluation.  PHE were managing this validation process for each of England, Wales, Scotland and Northern Ireland.

The UK Government showed significant confidence in Randox’s capability and conducted full engagement and planning subject to PHE acceptance of the Randox test.  When PHE acceptance was granted, the Randox part in the national plan had been prepared and was quickly initiated.

We understand that the national plan for the testing of key workers is exactly that, a national plan, inclusive of Northern Ireland.  Initially relatively small numbers of tests were sent to the areas of significant national threat in London.

The planning for the national distribution of test kits is being managed by the various relevant statutory agencies however Randox has made the case that tests should be made available locally.  Following that engagement, tests have now been made directly available within Northern Ireland and Randox will continue to support Northern Ireland within the UK national plan.

Randox have acted with speed and initiative throughout this crisis and will continue to ramp up our testing capability to support the national testing plan for key workers in Northern Ireland.

Every part of Randox’s business is focused on doing everything we can to support the Covid-19 testing programme, to both save lives and ensure the speediest possible return to a more normal society.

For more information please contact the Randox PR team by emailing randoxpr@randox.com

 

QNOSTICS

QCMD

BIOSCIENCES